IP Library Granted Patent US 7,087,215
Granted Patent B2
US 7,087,215 · App. 10/222,240 · Granted Aug 8, 2006

Methods of administering and enhancing absorption of pharmaceutical agents

Assignee: Generex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,087,215
App. No.
10/222,240
Granted
Aug 8, 2006
Kind
B2
Abstract

Pharmaceutical compositions comprising a macromolecular pharmaceutical agent in mixed micellar form are disclosed. The mixed micelles are formed from an alkali metal alkyl sulfate, and at least three different micelle-forming compounds as described in the specification. Micelle size ranges between about 1 and 10 nanometers. Methods for administering the compositions are also disclosed. A preferred method for administering the present composition is through the buccal region of the mouth, which has been demonstrated to achieve peak plasma levels of the pharmaceutical agent in about thirty minutes.

Claims (25)

1. A method of administering a pharmaceutical agent to the buccal mucosae of a patient comprising:

spraying a composition comprising said pharmaceutical agent in micellar form to said buccal mucosae with a metered dose dispenser, wherein

said pharmaceutical agent is selected from the group consisting of insulin, heparin, low molecular weight heparin, hirulog, hirugen, huridine, interferons, cytokines, mono and polyclonal antibodies, immunoglobins, chemotherapeutic agents, vaccines, glycoproteins, bacterial toxoids, hormones, calcitonins, glucagons like peptides, antibiotics, thrombolytic compounds, platelet inhibitors, DNA, RNA, gene therapeutics, antisense oligonucleotides, hypnotics, steroids, opioids, and painkillers, and wherein

said pharmaceutical agent is absorbed through said buccal mucosae and a peak plasma level of said pharmaceutical agent is obtained in less than about 1 hour.

2. The method of claim 1 , wherein said composition further comprises at least three micelle-forming compounds, said pharmaceutical agent is absorbed through the buccal mucosae, and a peak plasma level of said pharmaceutical agent is obtained in less than about 45 minutes.

3. The method of claim 2 , wherein a peak plasma level of said pharmaceutical agent is obtained in less than about 30 minutes.

4. The method of claim 1 , wherein said pharmaceutical agent is insulin.

5. The method of claim 3 , wherein said pharmaceutical agent is insulin.

6. A method of enhancing absorption of a pharmaceutical agent administered to the buccal mucosae of a patient comprising:

spraying a composition comprising said pharmaceutical agent in micellar form to said buccal mucosae with a metered dose dispenser, wherein

said pharmaceutical agent is selected from the group consisting of insulin, heparin, low molecular weight heparin, hirulog, hirugen, huridine, interferons, cytokines, mono and polyclonal antibodies, immunoglobulins, chemotherapeutic agents, vaccines, glycoproteins, bacterial toxoids, hormones, calcitonins, glucagons like peptides, antibiotics, thrombolytic compounds platelet inhibitors, DNA, RNA, gene therapeutics, antisense oligonucleotides, hypnotics, steroids, opioids fentanyl and pain killers, and wherein

said pharmaceutical agent is absorbed through said buccal mucosae and a peak plasma level of said pharmaceutical agent is obtained in less than about 1 hour.

7. The method of claim 6 , wherein said composition further comprises at least three micelle-forming compounds, said pharmaceutical agent is absorbed through the buccal mucosae, and a peak plasma level of said pharmaceutical agent is obtained in less than about 45 minutes.

8. The method of claim 7 , wherein a peak plasma level of said pharmaceutical agent is obtained in less than about 30 minutes.

9. The method of claim 6 , wherein said pulmonary pharmaceutical agent is insulin.

10. The method of claim 8 , wherein said pulmonary pharmaceutical agent is insulin.

11. The method of claim 6 , wherein said pharmaceutical agent is fentanyl.

12. The method of claim 8 , wherein said pharmaceutical agent is fentanyl.

13. A method of administering a pharmaceutical agent to the buccal mucosae of a patient comprising:

spraying a composition comprising said pharmaceutical agent and at least three micelle-forming compounds in micellar form to said buccal mucosae with a metered dose dispenser, wherein

said pharmaceutical agent is selected from the group consisting of insulin, heparin, low molecular weight heparin, hirulog, hirugen, huridine, interferons, cytokines, mono and polyclonal antibodies, immunoglobins, chemotherapeutic agents, vaccines, glycoproteins, bacterial toxoids, hormones, calcitonins, glucagons like peptides, antibiotics, thrombolytic compounds, platelet inhibitors, DNA, RNA, gene therapeutics, antisense oligonucleotides, hypnotics, steroids, opioids, and pain killers, and wherein

said pharmaceutical agent is absorbed through said buccal mucosae and a peak plasma level of said pharmaceutical agent is obtained in less than about 1 hour.

14. The method of claim 13 , wherein a peak plasma level of said pharmaceutical agent is obtained in less than about 30 minutes.

15. A method of administering insulin to the buccal mucosae of a patient comprising spraying a composition comprising said insulin and at least three micelle-forming compounds in micellar form to said buccal mucosae with a metered dose dispenser, wherein said insulin is absorbed through said buccal mucosae and a peak plasma level of said insulin is obtained in less than about 1 hour.

16. The method of claim 15 , wherein a peak plasma level of said insulin is obtained in less than about 30 minutes.

Assignments (7)
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: CRANSHIRE CAPITAL, L.P.
Reel/Frame 020753/0592 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: SMITHFIELD FIDUCIARY LLC
Reel/Frame 020753/0662 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: IROQUOIS CAPITAL OPPORTUNITY FUND, LP
Reel/Frame 020753/0704 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: PORTSIDE GROWTH AND OPPORTUNITY FUND
Reel/Frame 020753/0751 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: ROCKMORE INVESTMENT MASTER FUND LTD.
Reel/Frame 020753/0822 →
SECURITY AGREEMENT Recorded Apr 4, 2008
From: GENEREX PHARMACEUTICALS INC.
To: IROQUOIS MASTER FUND LTD.
Reel/Frame 020794/0416 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2002
From: MODI, PANKAJ
To: GENEREX PHARMACEUTICALS,INC.
Reel/Frame 013345/0045 →
Continuity (6)
Continuation In Part 0957450400 · May 19, 2000
Continuation In Part 0951928500 · Mar 6, 2000
Continuation In Part 0938628400 · Aug 31, 1999
Continuation In Part 0925146400 · Feb 17, 1999
Provisional Application 6011323900 · Dec 21, 1998
Related Publication 20030157029A1 · Aug 21, 2003